Precisio Biotix Therapeutics
Assaf Raz has extensive experience in research and development, holding positions such as Vice President R&D at Phagelux Inc. and Precisio Biotix Therapeutics. Previously, Assaf worked as a Research Associate at Rockefeller University and as an Adjunct Assistant Professor at Hunter College. Assaf has a PhD in Microbiology from The Rockefeller University and a BA in Biology from Tel Aviv University. Assaf is known for leading a team that developed the lysibody technology, a fusion between a human IgG antibody and a carbohydrate-binding domain of bacterial or bacteriophage origin.
This person is not in any teams
This person is not in any offices
Precisio Biotix Therapeutics
Precisio Biotix Therapeutics is US incorporated industry leader in precision antibacterial biological solutions; specifically the identification and development of lysin and phage products to combat bacterial infections or difficult to treat bacterial issues. Products created with lysins and phages are novel precision solutions to address the declining effectiveness of existing treatments. LysiThru™,the Company's industry-leading, high-throughput lysin screening system, is capable of rapidly creating new gram-positive and gram-negative lysins for almost every pathogen. The Company has a robust pipeline of commercial products with both Rx and consumer commercial opportunities. - Multiple gram positive and gram negative systemic lysins, with a focus on skin and lung infections. - Bactelide™, a sustained release biodegradable phage product to prevent and treat topical infections - Several topical lysins with consumer-oriented uses